Slides
Page 1
Retina experience redefined Ocular Therapeutix Corporate Overview April 2025
Page 2
2Retina experience redefined Forward Looking Statements and Disclaimers Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company’s product candidates, including the design of, and the timing of the enrollment of the Company’s SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company’s plans to advance the development of AXPAXLI and its other product candidates, including in additional indications such as NPDR; the size of potential markets for the Company’s product candidates; the potential utility or adoption, if approved, of any of the Company's product candidates; the sufficiency of the Company’s cash resources; and other statements containing the words "anticipate", "believe”, "estimate”, "expect”, "intend", “designed”, "goal”, "may", "might”, "plan”, "predict”, "project”, "target”, "potential”, "will”, "would”, "could”, "should”, "continue”, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA® or any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of DEXTENZA or any product or product candidate that receives regulatory approval; the initiation, design, timing, conduct, and outcomes of clinical trials, including the SOL-1 trial, the SOL-R trial, and the Company’s other ongoing clinical trials; the risk that the U.S. Food and Drug Administration, or FDA, will not agree with the Company’s interpretation of the written agreement under the SPA for the SOL-1 trial and the FDA's other written guidance for the SOL clinical program; the risk that even though the FDA has agreed with the overall design of the SOL clinical program, the FDA may not agree that the protocols and statistical analysis plans or the data generated by the SOL clinical program supports potential marketing approval, even if both SOL-1 and SOL-R are successful and meet their primary endpoints; the risk that the Company and the FDA may not agree on the registrational pathway for AXPAXLI for NPDR, DME or any other indication; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial will be predictive of final data from such trial, or whether data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; the timing of availability of data from clinical trials and expectations regarding the timing and sufficiency of regulatory submissions and approvals; the Company’s scientific approach and general development progress; the availability or commercial potential of the Company's product candidates; uncertainties inherent in estimating the Company’s cash runway, future expenses, and other financial results, including its ability to fund future operations, including clinical trials; the Company’s existing indebtedness and the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; the Company’s ability to enter into strategic alliances or generate additional funding on a timely basis, on favorable terms, or at all; and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. This presentation discusses investigational product candidates in development. Their efficacy and safety profiles have not been established, and they have not been approved for marketing by the FDA. This presentation contains references to the Company's trademarks and trade names and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this presentation may appear without the ® or symbols, but such references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, its rights or the rights of the applicable licensor to these trademarks and trade names. The Company does not intend its use or display of other companies' trademarks or trade names to imply a relationship with, or endorsement or sponsorship of it by, any other companies. AXPAXLI is a trade name which the Company uses to refer to its OTX-TKI product candidate. The FDA has not approved AXPAXLI or OTX-TKI as product names. 2
Page 3
3Retina experience redefined Retina experience redefined 3 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining Redefining Redefining treatment development outcomes
Page 4
4Retina experience redefined Retina experience redefined 4 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining treatment
Page 5
5Retina experience redefined Wet AMD: Significant Unmet Need AMD (age-related macular degeneration); OCT (optical coherence tomography). 1. Downs P . 2023 Retinal Pharmaceuticals Market Report: Global analysis for 2022 to 2028. Market Scope; 2023. 2. Ophthalmic Market Trends: Quarterly US Retina Edition: Q3- 2024 Analysis of Historical Trends and Latest Developments. Market Scope; 2024. 3. MacCumber et al. Canadian Ophthalmology Society. 2021; 10.1016/j.jcjo.2021.10.008. 4. Llorente-González S, et al. Acta Ophthalmol. 2022;100(2):e521-e531. 5. Evans RN, et al. JAMA Ophthalmol. 2020;138(10):1109. 90% of patients require injection every 1-3 months2 up to 12 injections/yr for patients up to 12 PTO days/yr for caregivers INJECTION BURDEN 1 72 83 94 105 116 12 Poor long-term visual outcomes Pulsatile dosing leads to fibrosis and atrophy4,5 FIBROSIS & ATROPHY 1.6M people with wet AMD in U.S.1 40% discontinue by one year3 Illustrative OCT
Page 6
6Retina experience redefined Incremental Durability Improvements Deliver Significant Market Opportunity 2006 2008 2010 2012 2014 2016 2018 2020 2022 2024 Vabysmo Eylea Lucentis $0.4B $15B GLOBAL BRANDED ANTI-VEGF REVENUE1 1. Data aggregated from company reports. Captures revenue across all labeled indications. Figure excludes BEOVU®. Q3 ’24 Revenues carried forward to Q4 ’24 to curate FY ’24 estimate. EYLEA® HD FDA approved in August 2023 captured in EYLEA® sales figures. 2. LUCENTIS® package insert. San Francisco, CA: Genentech, Inc. 2018. 3. Real-World Evidence (TRUCKEE Study): VABYSMO® offers 1-2 week extension over EYLEA® in switch patients. Study Results presented at Roche Ophthalmology Day, July 2024. 2012 2013 2014 2022 2023 2024 EYLEA v VABYSMOLUCENTIS v EYLEA +2 weeks +2 weeks LUCENTIS 44 Days3 57 Days330 Days2 $2.8B ~$4.4B 2006 2007 2008 $1.8B VABYSMO®EYLEA®LUCENTIS®
Page 7
7Retina experience redefined 6-12 Months3 Incremental Durability Improvements Deliver Significant Market Opportunity +MONTHS Future2012 2013 2014 EYLEA v VABYSMOLUCENTIS v EYLEA +2 weeks +2 weeks LUCENTIS 44 Days2 57 Days230 Days1 $2.8B 2006 2007 2008 $1.8B 2022 2023 2024 ~$4.4B AXPAXLI VABYSMO®EYLEA®LUCENTIS® Data aggregated from company reports. Captures revenue across all labeled indications. Figure excludes BEOVU®. Q3 ’24 Revenues carried forward to Q4 ’24 to curate FY ’24 estimate. EYLEA® HD FDA approved in August 2023 captured in EYLEA® sales figures. 1. LUCENTIS® package insert. San Francisco, CA: Genentech, Inc. 2018. 2. Real-World Evidence (TRUCKEE Study): VABYSMO® offers 1-2 week extension over EYLEA® in switch patients. Study Results presented at Roche Ophthalmology Day, July 2024. 3. AXPAXLI has not yet been approved by the U.S. FDA. Potential durability shown based on ongoing clinical trials.
Page 8
8Retina experience redefined AXPAXLI is Designed to Redefine the Market AXPAXLI Continuous and consistent delivery up to 12 months3 Single injection, single hydrogel3 Complete and predictable bioresorption3 Highly selective pan VEGF inhibitor1 Most potent TKI2 AXITINIB Multi-target Tyrosine Kinase Inhibitor (TKI) ELUTYX TECHNOLOGY Proprietary hydrogel Versatile, biocompatible, tunable platform3 Bioresorbable, Sustained Drug Delivery VEGF (vascular endothelial growth factor). 1. Zhao Y, et al. Oncologist. 2015;20(6):660-673. 2. Gross-Goupil M, et al. Clin Med Insights Oncol. 2013;7:269-277; Liang C, et al. Mol Ther Oncolytics. 2022;24:577-584. 3. Blizzard CD, Driscoll A, El-Hayek R, et al. Ocular implant containing a tyrosine kinase inhibitor. Published online September 13, 2022. Accessed September 26, 2022.
Page 9
9Retina experience redefined Retina experience redefined 9 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining development
Page 10
10Retina experience redefined AXPAXLI Wet AMD Clinical Program Summary wAMD (wet age-related macular degeneration); SoC (standard of care). 1. U.S. Phase I wet AMD trial (NCT06223958). AXPAXLI-treated N=15. Previous reported numbers (80% at 6 months, 73% at 10 months) include investigator discretion rescues. 2. Australia Phase I wet AMD Trial (NCT03630315). Treatment-naïve AXPAXLI monotherapy N=11. U.S.1 100% rescue free per protocol at 6 months; 80% at 10 months Australia2 Monotherapy activity in treatment-naive wAMD Evidence of Activity and Durability Designed to Show Superiority Designed to Show Non-Inferiority to SoC Proof of Concept Phase 3 Registrational Trials Primary endpoint at Week 36 with single AXPAXLI dose Primary endpoint at Week 56 with Q24W AXPAXLI dosing PHASE 1 SOL-1 SOL-R Complementary studies designed to show durability, repeatability, and flexibility
Page 11
11Retina experience redefined Redefining Development De-risking Registrational Program AMD (age-related macular degeneration). Compelling Phase 1 data De-risking Phase 3 designs De-risking regulatory path SOL-1 + SOL-R De-risking Complementary Trials AXPAXLI Registrational Program in Wet AMD
Page 12
12Retina experience redefined SOL-1 Design: AXPAXLI First Registration Study in Wet AMD Superiority Study Comparing a Single AXPAXLI Dose to a Single Aflibercept (2 mg) Dose at W36 AMD (age-related macular degeneration); BCVA (best-corrected visual acuity); ETDRS (Early Treatment Diabetic Retinopathy Study). Two-arm trial with ~300 total subjects randomized 1:1 Demonstrate that a single AXPAXLI dose is superior to a single aflibercept 2 mg dose based on proportion of subjects who maintained visual acuity, defined as <15 ETDRS letters of BCVA loss from baseline at Week 36 PRIMARY ENDPOINT (36 WEEKS)DESIGN R 1:1 SOL-1 -4-8 PRIMARY ENDPOINT AXPAXLI Aflibercept 2 mg Week AXPAXLI Aflibercept 2 mg Study visit 4 20 4412 288 24 40 4816 32 TRIAL SCHEMATIC 36 RANDOMIZATION (DAY 1) LOADING End of Year 2 76… … TOPLINE READOUT 52 SAFETY FOLLOW-UP MONTHLY VISITS (YEAR 1) MONTHLY VISITS (YEAR 2) 0
Page 13
13Retina experience redefined SOL-1 Design: AXPAXLI First Registration Study in Wet AMD Superiority Study Comparing a Single AXPAXLI Dose to a Single Aflibercept (2 mg) Dose at W36 AMD (age-related macular degeneration); BCVA (best-corrected visual acuity); ETDRS (Early Treatment Diabetic Retinopathy Study). R 1:1 SOL-1 -4-8 PRIMARY ENDPOINT AXPAXLI Aflibercept 2 mg Week AXPAXLI Aflibercept 2 mg Study visit 4 20 4412 288 24 40 4816 32 TRIAL SCHEMATIC 36 RANDOMIZATION (DAY 1) LOADING End of Year 2 76… … TOPLINE READOUT 52 SAFETY FOLLOW-UP MONTHLY VISITS (YEAR 1) MONTHLY VISITS (YEAR 2) 0 344 subjects randomized across >100 sites in U.S. and Argentina Fully randomized as of Dec 2024 Topline data expected 1Q 2026 SOL-1 STATUS Randomizing strong anti-VEGF responders Designed to establish AXPAXLI durability Designed to enable superiority claim on label FDA alignment through SPA SOL-1 De-Risking Elements
Page 14
14Retina experience redefined SOL-R Design: AXPAXLI Second Registration Study in Wet AMD Non-Inferiority Study Comparing AXPAXLI Q24W to Aflibercept (2mg) Q8W at W56 Three-arm trial with 555 total subjects randomized 2:2:1 Demonstrate that AXPAXLI is non-inferior to fixed-dose aflibercept 2mg Q8W with respect to mean change in BCVA at Week 56 from baseline in wet AMD patients Non-inferiority margin for the lower bound is -4.5 letters in BCVA at Week 56 PRIMARY ENDPOINT (56 WEEKS)DESIGN TRIAL SCHEMATIC AMD (age-related macular degeneration); BCVA (best-corrected visual acuity); VEGF (vascular endothelial growth factor). *Except BEOVU®. R 2:2:1 RANDOMIZATION (DAY 1) AXPAXLI Aflibercept 2 mg Aflibercept 8 mg Week -12 -4-20-24 -8-16 PRIMARY ENDPOINT LOADING 0 8 16 24 32 40 48 564 12 20 28 36 44 52 SOL-R AXPAXLI Aflibercept 2 mg Study visitAflibercept 8 mg End of Year 2 Evaluation Visits Any Anti VEGF* 72… … SAFETY FOLLOW-UP MONLTHY VISITS (YEAR 1) MONTHLY VISITS (YEAR 2) Q8W Q8W
Page 15
15Retina experience redefined SOL-R Design: AXPAXLI Second Registration Study in Wet AMD Non-Inferiority Study Comparing AXPAXLI Q24W to Aflibercept (2mg) Q8W at W56 TRIAL SCHEMATIC AMD (age-related macular degeneration); BCVA (best-corrected visual acuity); VEGF (vascular endothelial growth factor). *Except BEOVU®. R 2:2:1 RANDOMIZATION (DAY 1) AXPAXLI Aflibercept 2 mg Aflibercept 8 mg Week -12 -4-20-24 -8-16 PRIMARY ENDPOINT LOADING 0 8 16 24 32 40 48 564 12 20 28 36 44 52 SOL-R AXPAXLI Aflibercept 2 mg Study visitAflibercept 8 mg End of Year 2 Evaluation Visits Any Anti VEGF* 72… … SAFETY FOLLOW-UP MONLTHY VISITS (YEAR 1) MONTHLY VISITS (YEAR 2) Q8W Q8W Initially enrolled SOL-1 randomization failures Opened direct enrollment in Nov 2024 311 subjects enrolled across various stages of loading and randomization as of Jan 10, 2025 SOL-R STATUS Randomizing reliable anti-VEGF responders Designed to enable Q6M dosing on label Provides commercially relevant data FDA alignment based on Type C, other written responses SOL-R De-Risking Elements
Page 16
16Retina experience redefined Recent Updates to AXPAXLI Registrational Program in Wet AMD De-risking Registrational Program AMD (age-related macular degeneration). 1. Based on assumptions of how AXPAXLI is expected to perform. Recent changes to SOL-1 and SOL-R have the potential to further enhance and accelerate registrational program • SOL-1 SPA amendment approved by FDA • All subjects re-dosed at Weeks 52 and 76 • Primary endpoint unchanged at Week 36 • Subjects masked until Week 52 to facilitate re-dosing • Topline data expected in 1Q 2026 SOL-1 SOL-R • Re-dosing and exceptional retention in SOL-1 enables reduction of SOL-R trial size from 825 to 555 subjects • SOL-R maintains strong statistical powering of 90% to reach primary endpoint at Week 56 1 NDA Package • Complementary studies strategically designed to facilitate Q6 – Q12M dosing • Will address key questions on durability, flexibility and repeatability • Recent changes expected to accelerate time to NDA submission upon positive results
Page 17
17Retina experience redefined Diabetic Retinopathy (DR): Large and Unrealized Market Opportunity HIGH BURDEN, LOW TREATMENT RATE DR is the leading cause of blindness in the working-age population1 NPDR = 72% of total DR population <1% of NPDR patients treated 3,4 2.5M PDR 6.3M NPDR 8.8M DR patients (U.S.)2 PDR (proliferative diabetic retinopathy); NPDR (non-proliferative diabetic retinopathy). 1. Mohamed Q, et al. JAMA. 2007;298(8):902-916. 2. Market Scope. 2023 Retinal Pharmaceuticals Market Report. 3. Market Scope. 2022 Retinal Pharmaceuticals Market Report: Global Analysis for 2021 to 2027. Published August 2022. 4. Market Scope. US Retina Quarterly Update: Q2 2022 Analysis of Historical Trends and Latest Developments. Published August 2022.
Page 18
18Retina experience redefined HELIOS: Phase 1 Study of AXPAXLI in NPDR Multi-center, double-masked, randomized, parallel group study of AXPAXLI in mod- severe to severe NPDR without CI-DME Safety and tolerability of AXPAXLI PRIMARY ENDPOINTDESIGN TRIAL SCHEMATIC DRSS changes, rescue therapy, BCVA / CSFT, vision threatening complications (VTCs) SECONDARY ENDPOINT HELIOS Week 2:1 Randomization AXPAXLI Sham R 0 52 Monthly Study Visits Monthly Study Visits ∎AXPAXLI (N=13*) ∎Sham Control (N=8) *14 patients enrolled in AXPAXLI treatment arm, with one patient death unrelated to treatment. Ocular Therapeutix data on file as of May 22, 2024. BCVA (best-corrected visual acuity); DRSS (diabetic retinopathy severity scale); CSFT (central subfield thickness); NPDR (non-proliferative diabetic retinopathy); CI-DME (center involved diabetic macular edema).
Page 19
19Retina experience redefined Phase 1: No Disease Progression with AXPAXLI at Week 48 Ocular Therapeutix data on file as of May 22, 2024. PDR (proliferative diabetic retinopathy); CI-DME (center involved diabetic macular edema). 25.0% 12.5% 37.5% 0.0% 0.0% 0.0% 0% 5% 10% 15% 20% 25% 30% 35% 40% CI-DME PDR PDR or CI-DME AXPAXLI AXPAXLI AXPAXLI Percentage of Patients ∎Sham Control (N=8) ∎AXPAXLI (N=13) 0% in the AXPAXLI arm developed PDR or CI-DME at Week 48 compared to 37.5% in the sham arm MONOTHERAPY ACTIVITY IN NPDR
Page 20
20Retina experience redefined Phase 1: No Disease Progression with AXPAXLI at Week 48 Ocular Therapeutix data on file as of May 22, 2024. PDR (proliferative diabetic retinopathy); CI-DME (center involved diabetic macular edema). 25.0% 12.5% 37.5% 0.0% 0.0% 0.0% 0% 5% 10% 15% 20% 25% 30% 35% 40% CI-DME PDR PDR or CI-DME AXPAXLI AXPAXLI AXPAXLI Percentage of Patients ∎Sham Control (N=8) ∎AXPAXLI (N=13) BASELINE WEEK 48 Patient 11-007 Patient 13-001 Patient 15-004 Patient 16-005 Patient 16-006 Patient 11-008 \ BASELINE WEEK 48 Patient 12-002 Patient 16-009 IMPROVEMENT IN DIABETIC MACULAR EDEMA MONOTHERAPY ACTIVITY IN NPDR AXPAXLI-Treated Patients with non-CI-DME
Page 21
21Retina experience redefined Retina experience redefined 21 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining outcomes
Page 22
22Retina experience redefined Redefining Outcomes in Wet AMD: Keeping Patients on Treatment AMD (age-related macular degeneration). 1. MacCumber et al. Canadian Ophthalmology Society. 2021; 10.1016/j.jcjo.2021.10.008. 40% discontinue by one year1
Page 23
23Retina experience redefined Redefining Outcomes in Wet AMD: Keeping Patients on Treatment Ocular Therapeutix company estimates. AMD (age-related macular degeneration). If 35% discontinued treatment continue treatment >50K additional patients could avoid vision loss in the U.S. alone
Page 24
24Retina experience redefined Redefining Outcomes in Wet AMD: Keeping Patients on Treatment Ocular Therapeutix company estimates. AMD (age-related macular degeneration). If 25% discontinued treatment continue treatment >150K additional patients could avoid vision loss in the U.S. alone
Page 25
25Retina experience redefined Redefining Outcomes in Wet AMD: Keeping Patients on Treatment Ocular Therapeutix company estimates. AMD (age-related macular degeneration). If 15% discontinued treatment continue treatment >250K additional patients could avoid vision loss in the U.S. alone
Page 26
26Retina experience redefined Redefining Outcomes in Wet AMD: Addressing Pulsatile Dosing AMD (age-related macular degeneration); SoC (standard of care). Current SoC frequent, pulsatile dosing continue treatment pulsatile treatment
Page 27
27Retina experience redefined Redefining Outcomes in Wet AMD: Addressing Pulsatile Dosing AMD (age-related macular degeneration). AXPAXLI non-pulsatile treatment optimized treatment continue treatment
Page 28
28Retina experience redefined AXPAXLI Estimated U.S. Market Potential: 9.2M Patients1 wAMD (wet age-related macular degeneration); DME (diabetic macular edema); NPDR (non-proliferative diabetic retinopathy); PDR (proliferative diabetic retinopathy); RVO (retinal vein occlusion). *Excludes patients with DME as some patients have both NPDR/PDR and DME. 1. Downs P . 2023 Retinal Pharmaceuticals Market Report: Global analysis for 2022 to 2028. Market Scope; 2023. 2. Ophthalmic Market Trends: Quarterly US Retina Edition: Q3-2024 Analysis of Historical Trends and Latest Developments. Market Scope; 2024. wAMD: 1.65M Registrational Trials Ongoing Over half (52%) of anti-VEGF injections today are for wet AMD2 41x5 Mod-Severe NPDR: 2.7M* DME: 1.7M Registrational Trials in Planning Future Opportunities RVO: 1.4M PDR: 1.7M*
Page 29
29Retina experience redefined Retina experience redefined 29 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining Redefining Redefining treatment development outcomes
Page 30
30Retina experience redefined Redefining Treatment: AXPAXLI MoA (mechanism of action); TKI (tyrosine kinase inhibitor); wAMD (wet age-related macular degeneration); NPDR (non-proliferative diabetic retinopathy); DME (diabetic macular edema). 1. U.S. Phase I wet AMD trial (NCT06223958). AXPAXLI-treated N=15. Previous reported numbers (80% at 6 months, 73% at 10 months) include investigator discretion rescues. 2. Australia Phase I wet AMD Trial (NCT03630315). Treatment-naïve AXPAXLI monotherapy N=11. 3. HELIOS Phase I NPDR Trial (NCT05695417). AXPAXLI-treated N=14. Compelling Early ResultsProven MoA / Proven Delivery Potential for up to 12-month dosing across retinal diseases AXITINIB ELUTYX TECHNOLOGY wAMD NPDR 0% vision threatening complications at one year3 Improvement in DME3 Multi-targeted Highly selective Most potent TKI Bioresorbable Tunable Hydrogel 100% rescue free per protocol at 6 months1 80% rescue free per protocol at 10 months1 Monotherapy activity in treatment-naive wAMD2
Page 31
31Retina experience redefined Redefining Development: De-Risking Approach to Registrational Program VEGF (vascular endothelial growth factor); SPA (Special Protocol Agreement). Complementary trials with measures taken to de-risk outcomes Randomizing reliable anti-VEGF responders Designed to enable Q6M dosing on label Provides commercially relevant data FDA alignment based on Type C, other written responses SOL-R Non-Inferiority Trial Randomizing strong anti-VEGF responders Designed to establish AXPAXLI durability Designed to enable superiority claim on label FDA alignment through SPA SOL-1 Superiority Trial
Page 32
32Retina experience redefined Redefining the Market: AXPAXLI Designed with Ease of Adoption In Mind To succeed in the retinal vascular disease market, new products MUST meet three key criteria: Safe Effective Durable AdoptableFlexible To drive utilization QUICKLY, new products should also be: With AXPAXLI, we intend to check all these boxes, and more. Our retina experience tells us…
Page 33
33Retina experience redefined Resourced for Success: Infrastructure, Capital, and Expertise to Execute World-class team played key roles in the approvals of Lucentis, Eylea, and Vabysmo Expertise Infrastructure Clinical and commercial capabilities to execute successfully Capital Strong cash position of $392.1M expected to fund operations into 20281 1. As of December 31, 2024. Current cash expected to fund operations through topline data for both wet AMD pivotal trials, with support from continued DEXTENZA® growth; does not include expenses related to future clinical trials.
Page 34
34Retina experience redefined Retina experience redefined 34 • Our retina experience is redefining your retina experience Retina Experience Redefined Redefining Redefining Redefining treatment development outcomes
Page 35
Retina experience redefined THANK YOU. Investor Relations bslattery@ocutx.com